Compare PANL & FULC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | PANL | FULC |
|---|---|---|
| Founded | 1996 | 2015 |
| Country | United States | United States |
| Employees | N/A | 55 |
| Industry | Marine Transportation | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 543.2M | 462.2M |
| IPO Year | 2015 | 2019 |
| Metric | PANL | FULC |
|---|---|---|
| Price | $6.77 | $6.73 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 1 | 8 |
| Target Price | $9.00 | ★ $16.38 |
| AVG Volume (30 Days) | 675.1K | ★ 1.0M |
| Earning Date | 03-10-2026 | 04-30-2026 |
| Dividend Yield | ★ 2.92% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ 0.30 | N/A |
| Revenue | ★ $385,088,209.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $22.80 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $3.93 | $2.32 |
| 52 Week High | $9.39 | $15.74 |
| Indicator | PANL | FULC |
|---|---|---|
| Relative Strength Index (RSI) | 33.31 | 31.51 |
| Support Level | $6.59 | $6.33 |
| Resistance Level | $7.42 | $7.09 |
| Average True Range (ATR) | 0.31 | 0.39 |
| MACD | -0.06 | 0.02 |
| Stochastic Oscillator | 8.84 | 8.43 |
Pangaea Logistics Solutions Ltd and its subsidiaries provide seaborne drybulk logistics and transportation services. It transports various drybulk cargoes including grains, coal, iron, ore, pig, iron, hot briquetted iron, bauxite, alumina, cement clinker, dolomite, and limestone. The company provides ocean transportation services to clients utilizing an ocean-going fleet of motor vessels in the Handymax, Supramax, Ultramax, Panamax, and Post-Panamax segments. Its services include cargo loading, cargo discharge, vessel chartering, voyage planning, and technical vessel management. The company derives all of its revenues from contracts of affreightment, voyage charters and time charters. Geographically, it derives key revenue from the United States, followed by Canada, Germany, and others.
Fulcrum Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing small molecules for genetically defined rare diseases. Its product candidate, Pociredir, is an oral small molecule designed to induce fetal hemoglobin (HbF) and is in clinical development for sickle cell disease (SCD). The company completed dosing in the Phase 1b PIONEER trial evaluating pociredir in adults with SCD and reported clinical data showing clinically relevant HbF induction and improvements in markers of hemolysis and anemia. The company has also generated a pipeline of clinical-stage and pre-clinical programs targeting the root causes of rare genetic diseases.